The University Oxford has received \u00a31.17m of funding from Baszucki Group to assess the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P).
New technology could help identify fetal complications earlier in high-risk pregnancies. Researchers at the University of Oxford and collaborators have helped develop a wearable ultrasound patch capable of continuously monitoring fetal wellbeing during pregnancy, offering a potential new approach to identifying complications earlier in high-risk pregnancies.
Matthew Wood, Professor of Neuroscience in the Department of Paediatrics at the University of Oxford and Director & Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre, comments on new government plans to bring treatments for rare diseases a step closer.
Proximity to unsafe water strongly predicts schistosomiasis exposure, explaining sharp differences in infection and re\u2011infection across communities.
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford\u2019s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
Ahead of the forecast high temperatures over the UK\u2019s Spring Bank Holiday weekend, Dr Laurence Wainwright, Senior Departmental Lecturer at the Smith School of Enterprise & Environment and Senior Researcher in the Department of Psychiatry, outlines the unexpected risks.
Engineers and healthcare scientists from the University of Oxford and the University of Cape Town, South Africa, have come together to improve technologies for diagnosing disease and furthering our understanding of fundamental processes of disease. By advancing three-dimensional imaging of tissue at the microscopic scale, tissue-based analysis of changes in gene expression, and artificial intelligence methodologies, the team aims to generate new insights from tissue samples into health and disease.
Following the outbreak of Andes hantavirus disease on the cruise ship MV Hondius, UK universities and the UK Health Security Agency (UKHSA) have launched a new clinical study to characterise infection and disease associated with Andes hantavirus.
Researchers, clinicians, industry partners, bone cancer charities and patients recently gathered at St Catherine\u2019s College, University of Oxford, for the inaugural \u2018Oxford Workshop on Systems Biology and Therapeutic Approaches in Chondrosarcoma\u2019. The event brought together expertise across research and clinical care with the long-term aim to improve outcomes for patients with chondrosarcoma.
Scientists in Oxford have developed a faster way to identify the organisms causing bloodstream infections and to predict antibiotic resistance using rapid DNA sequencing, a move that could improve the care of sepsis patients in hospital and reduce unnecessary antibiotic use. Up to 245,000 people develop sepsis each year in the UK, and 48,000 die as a result.
The largest-ever study mapping genetic variants of HIV-1 around the world over the past 35 years shows that the regional distribution of different subtypes of the virus continues to evolve, posing a challenge to prevention and treatment efforts.
A major national study led by the University of Oxford to evaluate newborn screening for spinal muscular atrophy (SMA) has been funded by the National Institute for Health and Care Research (NIHR), marking a significant milestone towards the potential introduction of SMA screening across the UK.
Two research groups at the University of Oxford have been awarded funding through the prestigious International Cardiovascular Research Partnership Awards, to support high-quality international research collaborations that have the potential to accelerate progress towards improved understanding, prevention, diagnosis and treatment of cardiovascular disease.
A first-in-human pilot study, published in Nature Medicine, suggests that selectively removing a placenta-derived protein called soluble Fms-like tyrosine kinase 1 (sFlt-1) from the blood may be a safe and feasible way to help manage very preterm preeclampsia.
Poor mental health is an urgent issue in England.1 in 5 adults experience a common mental health problem. This impact is felt not only by individuals and families, but across society as a whole - in 2022, the Centre for Mental Health estimated that the economic and social costs of mental ill health in England was \u00a3300 billion a year - nearly double the annual NHS England budget.
A major international study published today in BMJ Public Health has found that a digitally enabled healthcare programme was associated with significant improvements in blood pressure control among people living with hypertension across sub-Saharan Africa.
The OpenBind consortium\u2019s first release of experimental data marks a milestone in efforts to improve how artificial intelligence (AI) is used in drug discovery.
Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) from Nuffield Department of Clinical Neurosciences (NDCN) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.
![\"A](\"https://www.medsci.ox.ac.uk/news/clinical-trial-of-ketogenic-therapy-for-early-psychosis-funded-by-baszucki-group/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n